Valerie Morisset - ELYM Old Chief Development
Executive
Valerie Morisset is Chief Development of ELYM Old
| Age | 54 |
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
Valerie Morisset Latest Insider Activity
Tracking and analyzing the buying and selling activities of Valerie Morisset against ELYM Old stock is an integral part of due diligence when investing in ELYM Old. Valerie Morisset insider activity provides valuable insight into whether ELYM Old is net buyers or sellers over its current business cycle. Note, ELYM Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell ELYM Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Valerie Morisset over six months ago Disposition of 10201 shares by Valerie Morisset of Eliem Therapeutics at 7.09 subject to Rule 16b-3 | ||
Valerie Morisset over six months ago Disposition of 30000 shares by Valerie Morisset of Eliem Therapeutics at 7.98 subject to Rule 16b-3 | ||
Valerie Morisset over six months ago Disposition of 50000 shares by Valerie Morisset of Eliem Therapeutics at 7.13 subject to Rule 16b-3 | ||
Valerie Morisset over six months ago Disposition of 42377 shares by Valerie Morisset of Eliem Therapeutics at 7.01 subject to Rule 16b-3 |
ELYM Old Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. ELYM Old's management efficiency ratios could be used to measure how well ELYM Old manages its routine affairs as well as how well it operates its assets and liabilities.ELYM Old currently holds 349 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. ELYM Old has a current ratio of 17.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ELYM Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas PharmD | Shattuck Labs | N/A | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| David CFA | PepGen | N/A | |
| Michelle MD | PepGen | 49 | |
| Michael Covarrubias | Rezolute | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Michael MD | Century Therapeutics | 53 | |
| Gopal MBBS | Rezolute | N/A | |
| Mary DeLena | PepGen | N/A | |
| Emiko Bryant | PepGen | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 51 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | 59 | |
| Michael Deperro | Rezolute | N/A | |
| MD MBA | Molecular Partners AG | 59 | |
| Douglas CPA | Century Therapeutics | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Renate Gloggner | Molecular Partners AG | 55 | |
| BSc MD | Aerovate Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
ELYM Old Leadership Team
Elected by the shareholders, the ELYM Old's board of directors comprises two types of representatives: ELYM Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ELYM. The board's role is to monitor ELYM Old's management team and ensure that shareholders' interests are well served. ELYM Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ELYM Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
ELYM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ELYM Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 23.84 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 0.99 X | |||
| EBITDA | (13.65 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in ELYM Stock
If you are still planning to invest in ELYM Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ELYM Old's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |